In the News

137 News Items found
Hands on keyboard
Memorial Sloan Kettering Cancer Center researchers have identified a feature in the DNA of breast cancer cells that might indicate the likelihood a woman's disease will become life threatening.
Sammy gets ready to swing a bat
Thanks to MSK’s expertise in treating young people with cancer, 16-year-old high school athlete Sammy is back to doing what he loves.
Craig Melvin
NBC News anchor Craig Melvin led MSK experts in a discussion about racial and age trends in colorectal cancer and when people should start screening for the disease.
DNA winding around histones
In the Lab
The MSK team’s goal was to get at the underlying defects in cells that these mutations cause.
Luis A. Diaz, MD
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce Luis Alberto Diaz, Jr., MD, Head of the Division of Solid Tumor Oncology; Grayer Family Chair at MSK, has been elected to the 10th class of Giants of Cancer Care® for his contributions in translational science.
SKI immunologist Ming Li
The new cells, which the scientists have dubbed killer innate-like T cells, differ in several notable ways from the conventional target of many immunotherapies.
rod-shaped bacteria
Feature
Discover how microbiome research is revealing the role that bacteria play in cancer treatment.
Five MSK researcher headshots
Read about the latest findings in immunotherapy from the 2021 annual meeting of the American Society of Clinical Oncology (ASCO).
Microscope image of cells in a mouse colon
MSK researchers identified a protein called ZFP36L2 that acts as a critical "molecular switch" controlling how gut cells repair themselves after injury — a mechanism that colorectal cancer hijacks to spread to other organs. The findings could point toward new treatments that exploit cancer cells' dependence on this protein to stop metastasis or overcome treatment resistance.
Luis Portiansky
In the Clinic
MSK researchers recently reported results of a phase 2 trial for GIST, a rare form of gastrointestinal cancer. The trial was based on years of lab work conducted by physician-scientist Ping Chi.